ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing treatments for chronic kidney and inflammatory diseases. ZyVersa has no approved products or revenue, and funds operations entirely through capital raises. The company's pipeline centers on two in-licensed drug candidates, both sourced from the University of Miami. VAR 200 is an injectable drug targeting cholesterol and lipid accumulation in kidney filtration cells, with a lead indication in focal segmental glomerulosclerosis (FSGS), a rare progressive kidney disease affecting roughly 40,000 people in the U.S. with no approved therapies. ZyVersa plans to initiate a Phase 2a trial for VAR 200 in FSGS and Alport syndrome patients in Q2-2026. IC 100 is a humanized monoclonal antibody designed to broadly suppress inflammation by inhibiting ASC, a protein component shared across multiple inflammasome types. The lead indication for IC 100 is cardiometabolic conditions associated with obesity, with an IND filing targeted for Q4-2026. ZyVersa's long-term plan is to advance both drugs through clinical trials, obtain FDA approval, and commercialize in the U.S. through a targeted sales force, while pursuing licensing or partnership arrangements in ex-U.S. markets. ZyVersa also intends to expand each drug into multiple indications to maximize the value of its licensed IP. Both licenses carry milestone obligations and royalties owed to licensors. ZyVersa operates with only 6 full-time employees, outsourcing manufacturing and clinical execution to contract organizations.